[Palliative treatment of pancreatic cancer].
Seufferlein
T
T
Klinik für Innere Medizin I, Universität Ulm. thomas.seufferlein@uniklinik-ulm.de
von Wichert
G
G
Adler
G
G
D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D021441:Carcinoma, Pancreatic Ductal / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D015994:Incidence; D044623:Nutrition Therapy; D059408:Pain Management; D010166:Palliative Care / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000401:mortality / Q000628:therapy*; D011788:Quality of Life; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D003841:Deoxycytidine; D066246:ErbB Receptors; D000093542:Gemcitabine